Business Editors/Health/Medical Writers
FREMONT, Calif.--(BUSINESS WIRE)--May 14, 2003
Cardima(R), Inc. (Nasdaq:CRDM) -- developer of the REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix microcatheter systems -- will host an evening reception and symposium showcasing the most recent developments in atrial fibrillation (AF) treatment using the REVELATION(R) family of microcatheters at the 24th Annual Scientific Session of the North American Society for Pacing and Electrophysiology (NASPE) to be held in Washington, D.C., from May 14 through 17, 2003. A total of approximately 6,500 physicians, related medical professionals and industry representatives are expected to attend the NASPE conference this year. The meeting will be held at the National Museum of Natural History at the Smithsonian Institute.
Cardima's symposium, "Is the Surgical Maze Cure Rate for AF Possible with Today's Emerging Linear Ablation Technology?," will be held on May 15, 2003, at 7:30 p.m. The symposium panel will be chaired by Warren M. Jackman, M.D., Professor of Medicine and Director of Clinical Electrophysiology, University of Oklahoma, and will feature recognized speakers from prestigious centers for electrophysiology, including Dr. Mauricio Scanavacca of the Heart Institute, Sao Paulo University, Brazil; Priv. Doz. Dr. med. Thorsten Lewalter, Medizinische Klinik und Poliklinik II University of Bonn, Germany; and Dr. Hugh Calkins of the Johns Hopkins Hospital, Baltimore, Maryland.
"We are expecting another standing-room only event as this prominent panel presents their experiences with the REVELATION(R) Tx, REVELATION(R) T-Flex and REVELATION(R) Helix," stated Gabriel Vegh, chief executive officer of Cardima. "Dr. Scanavacca will discuss left atrial ablation by percutaneous approach; Dr. Lewalter will address pulmonary vein (PV) ablation without stenosis; and Dr Calkins will discuss linear ablation as a less-invasive alternative to the MAZE procedure."
Cardima, Inc. developed the REVELATION(R) Tx linear ablation microcatheter system as a minimally invasive, single-use product that may have the potential for curing AF. In the United States, Cardima believes the REVELATION(R) Tx to be the first device to treat AF that has been submitted on a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA). Cardima submitted the PMA to the FDA on Sept. 20, 2002, and was granted expedited review status by the FDA on Nov. 5, 2002. Cardima announced on March 6, 2003, that the FDA has set a May 29, 2003, Circulatory System Devices Panel date to review the REVELATION(R) Tx PMA application. Clinical trial data from the REVELATION(R) Tx microcatheter demonstrated safety and promising efficacy.
